2026年全球核子醫學診斷市場報告

近年來，核醫診斷市場發展迅速，預計將從2025年的78.8億美元成長到2026年的88.4億美元，複合年成長率達12.2%。過去幾年的成長主要歸功於放射性示蹤劑在診斷中的應用日益廣泛、醫院核子醫學科室的擴建、功能性影像需求的成長、Technetium放射性藥物的廣泛應用以及核子醫學領域臨床研究的進展。

預計未來幾年核醫診斷市場將快速成長，到2030年市場規模將達到137.7億美元，複合年成長率（CAGR）為11.7%。預測期內的成長要素包括：對診療一體化（治療診斷學）投資的增加、精準腫瘤診斷技術的日益普及、PET成像基礎設施的擴展、對靶向放射性藥物研發的日益重視以及對核診斷的監管支持力度加大。預測期內的主要趨勢包括：基於PET的診斷放射性藥物的日益普及、對個性化核診斷的需求不斷成長、影像和治療應用的融合程度不斷提高、以腫瘤學為重點的核醫學檢測的擴展以及對短半衰期放射性示踪劑的日益關注。

預計未來幾年，癌症發生率的不斷上升將推動核醫學診斷市場的擴張。癌症是指一組以異常細胞不受控制地生長和擴散為特徵的疾病，這些異常細胞可在體內形成腫瘤。癌症發生率上升的主要原因是全球人口老化。癌症風險老齡化成長而顯著增加，而醫學進步也在延長壽命。核子醫學診斷利用放射性物質，透過專用後續觀察設備識別這些物質，從而產生器官結構和功能的詳細影像，在多種癌症的檢測、分期和追蹤中發揮關鍵作用。例如，根據美國國家癌症研究所2025年5月發布的數據，2022年全球約有2,000萬人被診斷出罹患癌症，導致970萬人死亡。預計到2050年，每年新增病例將增加至3,300萬例，癌症相關死亡人數將達1,820萬人。因此，日益加重的癌症負擔正在顯著推動核醫診斷市場的成長。

核子醫學診斷市場的主要企業正致力於提供先進的醫療解決方案，以增強其競爭優勢。先進的醫療技術指的是旨在幫助改善患者預後、提高護理標準和改善健康管理的創新工具和系統。例如，2023年8月，總部位於馬來西亞的醫療服務供應商鷹閣醫院宣布開設專門的核子醫學科。該科室是一家配備最尖端科技並由訓練有素的專業人員支持的專業醫院，能夠透過核子醫學掃描術診斷技術實現疾病的早期發現、準確診斷和治療。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球核子醫學診斷市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 主要原料、資源和供應商清單
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章 全球市場趨勢與策略

• 關鍵技術和未來趨勢
  • 生物技術、基因組學和精準醫學
  • 數位化、雲端運算、巨量資料、網路安全
  • 工業4.0和智慧製造
  • 人工智慧（AI）和自主人工智慧
  • 永續性、氣候技術和循環經濟
• 主要趨勢
  • PET診斷放射性藥物的應用日益增多
  • 對個人化核診斷的需求日益成長
  • 診斷影像與治療應用融合方面的進展
  • 擴大核子醫學檢測範圍，重點關注腫瘤學
  • 人們越來越關注短壽命放射性示蹤劑

第5章 終端用戶產業市場分析

• 醫院和診斷中心
• 核子醫學診所
• 研究所
• 腫瘤中心
• 學術醫療機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球核子醫學診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
• 全球核子醫學診斷市場規模、比較及成長率分析
• 全球核子醫學診斷市場表現：規模與成長，2020-2025年
• 全球核子醫學診斷市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場規模（TAM）

第9章 市場細分

• 按類型
• SPECT放射性藥物，PET放射性藥物
• 透過使用
• 心臟病學、甲狀腺病學、神經病學、腫瘤學及其他應用領域
• 最終用戶
• 醫院、診斷中心和研究機構
• 按類型細分：SPECT放射性藥物
• 用於SPECT的Technetium-99m放射性藥物、碘-123放射性藥物、鉈-201放射性藥物和其他放射性藥物
• 按類型細分：PET放射性藥物
• 氟-18放射性藥物、碳-11放射性藥物、鎵-68放射性藥物和其他PET放射性藥物

第10章 區域與國家分析

• 全球核子醫學診斷市場：依地區、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測
• 全球核子醫學診斷市場：依國家、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 核子醫學診斷市場：競爭格局及市場佔有率（2024年）
• 核子醫學診斷市場：公司估值矩陣
• 核子醫學診斷市場：公司概況
  • Siemens AG
  • Bayer Aktiengesellschaft
  • Novartis AG
  • GE Healthcare Technologies Inc.
  • Perkin Elmer Inc.

第37章：其他領先和創新企業

• Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen-und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion（Canada）Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

• 2030年核子醫學診斷市場：提供新機會的國家
• 2030年核子醫學診斷市場：新興細分市場機會
• 2030年核子醫學診斷市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手策略

第41章附錄

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

Tariffs are impacting the nuclear medicine diagnostics market by increasing costs of imported radioisotopes, cyclotron components, imaging accessories, and specialized handling equipment. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported radiopharmaceutical inputs, while Asia-Pacific faces higher production and export costs. These tariffs are raising diagnostic procedure costs and affecting supply chain reliability. However, they are also encouraging domestic radioisotope production, regional supply chain strengthening, and investment in local radiopharmaceutical manufacturing capabilities.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with a nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.88 billion in 2025 to $8.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing use of radioactive tracers in diagnostics, expansion of hospital-based nuclear medicine units, rising demand for functional imaging, availability of technetium-based radiopharmaceuticals, growth of clinical research in nuclear medicine.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing investments in theranostics, rising adoption of precision oncology diagnostics, expansion of PET imaging infrastructure, growing focus on targeted radiopharmaceutical development, increasing regulatory support for nuclear diagnostics. Major trends in the forecast period include increasing adoption of pet-based diagnostic radiopharmaceuticals, rising demand for personalized nuclear diagnostics, growing integration of imaging and therapeutic applications, expansion of oncology-focused nuclear medicine procedures, enhanced focus on short-half-life radiotracers.

The growing incidence of cancer is anticipated to drive the expansion of the nuclear medicine diagnostics market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which may form tumors within the body. The increasing prevalence of cancer is largely attributed to the aging global population, as cancer risk rises significantly with age, along with advances in healthcare that are extending life expectancy. Nuclear medicine diagnostics plays a critical role in the detection, staging, and monitoring of multiple cancer types by using radioactive substances that can be identified by specialized imaging systems to generate detailed images of organ structure and function. For example, in May 2025, data from the National Cancer Institute indicated that in 2022 nearly 20 million people worldwide were diagnosed with cancer and 9.7 million deaths were recorded, with projections estimating an increase to 33 million new cases and 18.2 million cancer-related deaths annually by 2050. As a result, the rising burden of cancer is contributing significantly to the growth of the nuclear medicine diagnostics market.

Leading companies operating in the nuclear medicine diagnostics market are increasingly focused on launching advanced medical solutions to strengthen their competitive positioning. Advanced medical technologies refer to innovative tools and systems designed to enhance patient outcomes, elevate standards of care, and support improved health management. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based healthcare services provider, announced the launch of a dedicated Nuclear Medicine Unit. This unit is a specialized hospital facility equipped with state-of-the-art technology and supported by trained professionals, enabling early detection, accurate diagnosis, and treatment of diseases through nuclear medicine imaging techniques.

In March 2025, GE HealthCare Technologies, Inc., a United States-based medical technology and pharmaceutical company, acquired Nihon Medi Physics Co., Ltd. for an undisclosed consideration. Through this acquisition, GE HealthCare seeks to incorporate Nihon Medi Physics' strong capabilities in radiopharmaceutical development and manufacturing, thereby enhancing its ability to supply next-generation molecular imaging agents across neurology, cardiology, and oncology applications. Nihon Medi Physics Co., Ltd. is a Japan-based radiopharmaceutical company specializing in the development and supply of radioactive pharmaceuticals used in diagnostic nuclear medicine procedures.

Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
• 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
• 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
• Subsegments:
• 1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals
• 2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
• Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.; Mallinckrodt Pharmaceuticals; Bracco Diagnostics Inc.; Lantheus Holdings Inc.; IBA Radiopharma Solutions; Curium SAS; Eckert & Ziegler Strahlen- und Medizintechnik AG; Advanced Accelerator Applications; Telix Pharmaceuticals Limited; Nordion (Canada) Inc.; NorthStar Medical Technologies LLC; SHINE Medical Technologies LLC; Navidea Biopharmaceuticals Inc.; Cyclopharm Limited; Isologic Innovative Radiopharmaceuticals; Clarity Pharmaceuticals Limited; Actinium Pharmaceuticals Inc.; Jubilant DraxImage Inc.; PharmaLogic Holdings Corp; Institute of Isotopes Co Ltd.; Theragnostics Ltd.; EczacIbasI-Monrol Nuclear Products Co.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Nuclear Medicine Diagnostics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Nuclear Medicine Diagnostics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Nuclear Medicine Diagnostics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Nuclear Medicine Diagnostics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Pet-Based Diagnostic Radiopharmaceuticals
  • 4.2.2 Rising Demand For Personalized Nuclear Diagnostics
  • 4.2.3 Growing Integration Of Imaging And Therapeutic Applications
  • 4.2.4 Expansion Of Oncology-Focused Nuclear Medicine Procedures
  • 4.2.5 Enhanced Focus On Short-Half-Life Radiotracers

5. Nuclear Medicine Diagnostics Market Analysis Of End Use Industries

• 5.1 Hospitals And Diagnostic Centers
• 5.2 Nuclear Medicine Clinics
• 5.3 Research Institutes
• 5.4 Oncology Centers
• 5.5 Academic Medical Institutions

6. Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nuclear Medicine Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Nuclear Medicine Diagnostics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nuclear Medicine Diagnostics Market Segmentation

• 9.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
• 9.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiology, Thyroid, Neurology, Oncology, Other Applications
• 9.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Diagnostic Centers, Research Institutes
• 9.4. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of SPECT Radiopharmaceuticals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals
• 9.5. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of PET Radiopharmaceuticals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals

10. Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 10.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nuclear Medicine Diagnostics Market

• 11.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nuclear Medicine Diagnostics Market

• 12.1. China Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nuclear Medicine Diagnostics Market

• 13.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nuclear Medicine Diagnostics Market

• 14.1. Japan Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nuclear Medicine Diagnostics Market

• 15.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nuclear Medicine Diagnostics Market

• 16.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nuclear Medicine Diagnostics Market

• 17.1. South Korea Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nuclear Medicine Diagnostics Market

• 18.1. Taiwan Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nuclear Medicine Diagnostics Market

• 19.1. South East Asia Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nuclear Medicine Diagnostics Market

• 20.1. Western Europe Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nuclear Medicine Diagnostics Market

• 21.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nuclear Medicine Diagnostics Market

• 22.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nuclear Medicine Diagnostics Market

• 23.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nuclear Medicine Diagnostics Market

• 24.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nuclear Medicine Diagnostics Market

• 25.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nuclear Medicine Diagnostics Market

• 26.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nuclear Medicine Diagnostics Market

• 27.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nuclear Medicine Diagnostics Market

• 28.1. North America Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nuclear Medicine Diagnostics Market

• 29.1. USA Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nuclear Medicine Diagnostics Market

• 30.1. Canada Nuclear Medicine Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nuclear Medicine Diagnostics Market

• 31.1. South America Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nuclear Medicine Diagnostics Market

• 32.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nuclear Medicine Diagnostics Market

• 33.1. Middle East Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nuclear Medicine Diagnostics Market

• 34.1. Africa Nuclear Medicine Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nuclear Medicine Diagnostics Market Regulatory and Investment Landscape

36. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 36.1. Nuclear Medicine Diagnostics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Nuclear Medicine Diagnostics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Nuclear Medicine Diagnostics Market Company Profiles
  • 36.3.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited

38. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

40. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

• 40.1 Nuclear Medicine Diagnostics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Nuclear Medicine Diagnostics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Nuclear Medicine Diagnostics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer